Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17070660 | 0.85 | — | — | |
| SCHEMBL17068679 | 0.82 | HTR2A (0.31) | HTR2CHTR2AHTR2B | |
| SCHEMBL18015226 | 0.78 | HTR2A (0.36) | HTR2CHTR2AHTR2BPDE4BRIPK1 | |
| SCHEMBL17068720 | 0.77 | — | — | |
| SCHEMBL16769032 | 0.76 | HTR2C (0.38) | HTR2CHTR2AHTR2BPDE4BPDE4A | |
| SCHEMBL16769031 | 0.76 | HTR2A (0.38) | HTR2CHTR2AHTR2BPDE4BPDE4A | |
| SCHEMBL12366408 | 0.76 | HTR2A (0.38) | HTR2CHTR2AHTR2BPDE4BPDE4A | |
| SCHEMBL12759143 | 0.76 | HTR2C (0.35) | HTR2CHTR2AHTR2BPDE4BPDE4A | |
| SCHEMBL21609932 | 0.75 | APOBEC3G (0.38) | HTR2CHTR2AHTR2BPDE4BPDE4A | |
| SCHEMBL18626141 | 0.75 | ALDH1A1 (0.39) | HTR2CHTR2AHTR2BPDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9523038-B2 | Dihydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20150252264-A1 | DIHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252264-A1 | DIHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, CNKSR1, DRG1 | HTR2C 651/4885HTR2A 744/4885HTR2B 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.